ACBD4
Acyl-CoA-binding domain-containing protein 4
Also known as: ACBD4_HUMAN, FLJ13322
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8NC06
- Gene
- ACBD4
- Ensembl
- ENSG00000181513
- Chromosome
- 17
- Canonical length
- 268 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Vesicles
OverviewNCBI Gene
This gene encodes a member of the acyl-coenzyme A binding domain containing protein family. All family members contain the conserved acyl-Coenzyme A binding domain, which binds acyl-CoA thiol esters. They are thought to play roles in acyl-CoA dependent lipid metabolism. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2008]
Canonical amino-acid sequenceUniProt
268 residues, UniProt reviewed canonical sequence.
>Q8NC06|ACBD4
1 MGTEKESPEP DCQKQFQAAV SVIQNLPKNG SYRPSYEEML RFYSYYKQAT MGPCLVPRPG
61 FWDPIGRYKW DAWNSLGKMS REEAMSAYIT EMKLVAQKVI DTVPLGEVAE DMFGYFEPLY
121 QVIPDMPRPP ETFLRRVTGW KEQVVNGDVG AVSEPPCLPK EPAPPSPESH SPRDLDSEVF
181 CDSLEQLEPE LSSGQHLEES VIPGTAPCPP QRKRGCGAAR RGPRSWTCGC WGQFEHYRRA
241 CRRCRRGCRA WRACPGPLSS LTLSVRLELocalizationUniProt · AlphaFold · HPA
Whether an antibody against ACBD4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 91 nTPM
Expression across tissuesHPA
Tissue
- liver: 91 nTPM
- duodenum: 28 nTPM
- small intestine: 24 nTPM
- kidney: 24 nTPM
- fallopian tube: 22 nTPM
- blood vessel: 22 nTPM
Single-cell type
- enterocytes: 62 nCPM
- proximal tubule cells: 40 nCPM
- epididymal efferent duct absorptive cells: 31 nCPM
- paneth cells: 31 nCPM
- hepatocytes: 30 nCPM
- adipocytes: 27 nCPM
Immune cell
- naive B-cell: 5 nTPM
- basophil: 4.4 nTPM
- naive CD8 T-cell: 4.3 nTPM
- T-reg: 4.3 nTPM
- NK-cell: 4 nTPM
- memory B-cell: 3.7 nTPM
Brain region
- spinal cord: 16 nTPM
- amygdala: 16 nTPM
- thalamus: 16 nTPM
- medulla oblongata: 15 nTPM
- midbrain: 15 nTPM
- basal ganglia: 15 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.93
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.3
- DepMap mean gene effect
- -0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ACBD4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ACBD4 as an antibody target. Whether an autoantibody or antibody against ACBD4 could matter depends on whether native ACBD4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ACBD4 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ACBD4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...